ArticleBeyoglu eye journal2026
Comparison of Patients with Diabetic Macular Edema Undergoing Early versus Late Switch from Intravitreal Anti-VEGF Therapy to Dexamethasone Implant.
Article in Beyoglu eye journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To compare anatomical and functional outcomes in patients with diabetic macular edema who exhibited a suboptimal response to intravitreal anti-VEGF therapy and underwent early (<6 months) versus late (≥6 months) switch to an intravitreal dexamethasone implant. Methods: This retrospective comparative study included 141 eyes of 141 patients with diabetic macular edema. Patients received at least three consecutive anti-VEGF injections without adequate anatomical or functional response and were subsequently switched to a dexamethasone implant. Patients were divided into two groups: early switch (<6 months) and late switch (≥6 months). Best-corrected visual acuity, central macular thickness, optical coherence tomography biomarkers, intraocular pressure, lens status, number of injections, and complications were analyzed. Results: Of 141 patients (79 females, 62 males; mean age 65.3±8.9 years), 49 were in the early switch group and 92 were in the late switch group. At baseline, best-corrected visual acuity was marginally better in the late switch group (p=0.049), while baseline central subfield thickness was comparable (p=0.35). After switching, both groups showed a significant reduction in central subfield thickness (p<0.01), with no difference between the groups (p=0.58). Best-corrected visual acuity improved significantly in both groups; however, visual gain was greater in the early switch group (p=0.038). The mean number of total intravitreal injections was significantly higher in the late switch group (p<0.01). Mean intraocular pressure increased from 16.3 to 18.0 mmHg in both groups (p<0.01), with no intergroup difference. Thirty-one patients required cataract surgery during follow-up, without correlation with switch timing. Optical coherence tomography biomarkers revealed that patients with ellipsoid zone disruption had poorer BCVA outcomes, while those with subfoveal serous detachment exhibited greater central subfield thickness reduction (p<0.05). Conclusion: Early switch from anti-VEGF to a dexamethasone implant in refractory diabetic macular edema provides superior functional outcomes and reduces treatment burden compared with late switch, despite similar anatomical improvements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.